TY - JOUR
T1 - Pain in neuromyelitis optica and its effect on quality of life
T2 - A cross-sectional study
AU - Kanamori, Y.
AU - Nakashima, I.
AU - Takai, Y.
AU - Nishiyama, S.
AU - Kuroda, H.
AU - Takahashi, T.
AU - Kanaoka-Suzuki, C.
AU - Misu, T.
AU - Fujihara, K.
AU - Itoyama, Y.
N1 - Funding Information:
Dr. Kanamori reports no disclosures. Dr. Nakashima has received funding for travel and received speaker honoraria from Bayer Schering Pharma and Biogen Idec; served as editor for Multiple Sclerosis International; and has received research funding from Mitsubishi Chemical Medience Corporation and Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology. Dr. Takai, Dr. Nishiyama, Dr. Kuroda, Dr. Takahashi, and Dr. Kanaoka-Suzuki report no disclosures. Dr. Misu has received speaker honoraria from Bayer Schering Pharma and Asteras Pharma Inc. and has received research support from Bayer Schering Pharma, Biogen Idec, Asahi Kasei Kuraray Medical Co., The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, and Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan. Dr. Fujihara serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, and Merck Serono; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, and Asahi Kasei Kuraray Medical Co., Ltd.; serves on the editorial board of Clinical and Experimental Neuroimmunology; receives publishing royalties for Clinical Practice Guide of Orthopedic Surgery (Bunkodo, 2007); and receives/has received research support from Bayer Schering Pharma, Biogen Idec, Asahi Kasei Kuraray Medical Co., The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, Eisai Inc., and Kowa Pharmaceuticals America, Inc., and Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan. Dr. Itoyama has received funding for travel and speaker honoraria from Bayer Schering Pharma and has received research support from Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan.
Funding Information:
Study funding: Supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology ( 20390241, 21790828, 22229008 ) and the Ministry of Health, Labor and Welfare of Japan.
PY - 2011/8/16
Y1 - 2011/8/16
N2 - Objective: To assess the features of pain and its impact on the health-related quality of life (HRQOL) in neuromyelitis optica (NMO). Methods: We analyzed 37 patients withNMOorNMOspectrum disorders seen at the Department of Neurology Tohoku University Hospital Sendai Japan, during the period from November 2008 to February 2009. A total of 35 of them were aquaporin-4 antibody-positive. We used Short Form Brief Pain Inventory (BPI) to assess pain and Short Form 36-item (SF-36) health survey to evaluate the HRQOL. Fifty-one patients with multiple sclerosis (MS) were also studied for comparison. Results: Pain in NMO (83.8%) was far more common than in MS (47.1%). The Pain Severity Index score in BPI was significantly higher in NMO than in MS, and patients' daily life assessed by BPI was highly interfered by pain in NMO as compared with MS. Pain involving the trunk and both legs was much more frequent in NMO than in MS. SF-36 scores in NMO were lower than MS, especially in bodily pain. Conclusion: Our study showed that pain in NMO is more frequent and severe than in MS and that pain has a grave impact on NMO patients' daily life and HRQOL. Therapy to relieve pain is expected to improve their HRQOL.
AB - Objective: To assess the features of pain and its impact on the health-related quality of life (HRQOL) in neuromyelitis optica (NMO). Methods: We analyzed 37 patients withNMOorNMOspectrum disorders seen at the Department of Neurology Tohoku University Hospital Sendai Japan, during the period from November 2008 to February 2009. A total of 35 of them were aquaporin-4 antibody-positive. We used Short Form Brief Pain Inventory (BPI) to assess pain and Short Form 36-item (SF-36) health survey to evaluate the HRQOL. Fifty-one patients with multiple sclerosis (MS) were also studied for comparison. Results: Pain in NMO (83.8%) was far more common than in MS (47.1%). The Pain Severity Index score in BPI was significantly higher in NMO than in MS, and patients' daily life assessed by BPI was highly interfered by pain in NMO as compared with MS. Pain involving the trunk and both legs was much more frequent in NMO than in MS. SF-36 scores in NMO were lower than MS, especially in bodily pain. Conclusion: Our study showed that pain in NMO is more frequent and severe than in MS and that pain has a grave impact on NMO patients' daily life and HRQOL. Therapy to relieve pain is expected to improve their HRQOL.
UR - http://www.scopus.com/inward/record.url?scp=80055085027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055085027&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318229e694
DO - 10.1212/WNL.0b013e318229e694
M3 - Article
C2 - 21813781
AN - SCOPUS:80055085027
VL - 77
SP - 652
EP - 658
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 7
ER -